Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2697)	2/11/2010 9:56:10 PM
From: Jibacoa	Respond to of 3722

O.T. Looking at the general market and answering a coment on another thread. <<Interesting that CYCC didn't give up all the gains toward the close.>> The general market also didn't give up most of its gains toward the close. Of course, there is still a lot of volatility and enough reasons to be worried from the economy point of view. But the NAZ closed just 2 points below its intraday H and the DOW and S&P were more closer to their Hs than to their Ls. The three don't look bad, with stochastics continuing to rise from the early Feb Ls. However, resistant points aren't too far above.<g> The Dow at 10280- 10315 The S&P at the 1100 The NAZ at 2000 CYCC traded a penny below its Feb 4 H. It has closed its Feb 4 UG and stochastics are close to 40 (it dipped below 20 on Feb3 ). If it can close above the Feb 4 H and with some good news it could retest the resistance at $3 The intraday H on Jan8, at the end of the 3 days spike, was $4.08 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2697)	4/1/2010 10:54:44 AM
From: Jibacoa	Respond to of 3722

CYCC is up 5.12% with volume > 1.2M still < 1/3 its ADV.<g> bigcharts.marketwatch.com It announced that six abstracts highlighting translational and preclinical data for its cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research Annual Meeting, to be held this month in Washington, DC. The abstracts can be accessed through the AACR website, www.aacr.org. Sapacitabine: "Understanding the pathways involved in the repair of CNDAC induced DNA damage" On Apr 20 Abstract Number: 3502 Seliciclib and Second Generation CDK Inhibitors: "Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer" On Apr 18 Abstract Number: 22 "Therapeutic potential of CDK inhibitors in MLL leukemias" On Apr 20 Abstract Number: 3886 "A novel derivative of the CDK inhibitor roscovitine that induces apoptosis in CLL and overcomes stromal cell-mediated protection" On Apr 20 Abstract Number: 4431 CYC116: "Tumor cell resistance mechanisms to aurora kinase inhibitors" On Apr 18 Abstract Number: 633 Plk1 Inhibitors: "Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1) selective small molecule inhibitors" On Apr 20 Abstract Number: 4435 As I mentioned, I will add after it trades above th resistance at $2.50 <g> bigcharts.marketwatch.com Bernard